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Abstract
Objective: Four types of antipsychotic-induced movement disorders: tardive dyskinesia (TD), parkinsonism, akathisia and
tardive dystonia, subtypes of TD (orofacial and limb truncal dyskinesia), subtypes of parkinsonism (rest tremor, rigidity, and
bradykinesia), as well as a principal-factor of the movement disorders and their subtypes, were examined for association
with variation in 7 candidate genes (GRIN2B, GRIN2A, HSPG2, DRD3, DRD4, HTR2C, and NQO1).
Methods: Naturalistic study of 168 white long-stay patients with chronic mental illness requiring long-term antipsychotic
treatment, examined by the same rater at least two times over a 4-year period, with a mean follow-up time of 1.1 years, with
validated scales for TD, parkinsonism, akathisia, and tardive dystonia. The authors genotyped 45 tag SNPs in 7 candidate
genes, associated with movement disorders or schizophrenia in previous studies. Genotype and allele frequency
comparisons were performed with multiple regression methods for continuous movement disorders.
Results: Various tag SNPs reached nominal significance; TD with rs1345423, rs7192557, rs1650420, as well as rs11644461;
orofacial dyskinesia with rs7192557, rs1650420, as well as rs4911871; limb truncal dyskinesia with rs1345423, rs7192557,
rs1650420, as well as rs11866328; bradykinesia with rs2192970; akathisia with rs324035; and the principal-factor with
rs10772715. After controlling for multiple testing, no significant results remained.
Conclusions: The findings suggest that selected tag SNPs are not associated with a susceptibility to movement disorders.
However, as the sample size was small and previous studies show inconsistent results, definite conclusions cannot be made.
Replication is needed in larger study samples, preferably in longitudinal studies which take the fluctuating course of
movement disorders and gene-environment interactions into account.
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Introduction
Soon after the introduction of antipsychotic medication in 1952,
movement disorders emerged as a complication of treatment. To
date, they remain a major concern in antipsychotic treatment. Of
the different movement disorders, tardive dyskinesia (TD) is the
most extensively investigated. TD and other movement disorders
are associated with social stigmatization, physical disabilities and
poorer quality of life. In addition, they play a role in non-
compliance and, therefore, risk of psychotic relapse [1–3].
A central problem in the management of movement disorders is
the lack of clear genetic and non-genetic risk factors that would
allow for early identification and prevention. It would be helpful if
movement disorders could be predicted from a minimal number of
genetic susceptibility loci in candidate genes in combination with
demographic, clinical or pharmacological data. In order to identify
individuals at risk, pharmacogenetic studies of genetic factors that
contribute to interpersonal differences in susceptibility for medi-
cation-related adverse effects are needed [4]. Family studies
suggest an important genetic component to the risk for movement
disorders [4–9]. A recent meta-analysis on the prevalence of
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dyskinesia and parkinsonism reported spontaneous dyskinesia and
parkinsonism in antipsychotic naı¨ve patients with schizophrenia,
and a higher prevalence of dyskinesia and parkinsonism in healthy
family members of patients with schizophrenia, compared to
matched controls [10].
Antipsychotic-induced movement disorders [11,12] can be
classified as acute or tardive. Acute syndromes appear within
hours/days or weeks after starting antipsychotics or increasing the
dosage (or cessation of anticholinergics). Examples of these are
parkinsonism and akathisia. Tardive syndromes develop after
months or years of treatment with antipsychotics, examples being
TD and tardive dystonia. Initially, the term ‘tardive’ (delayed) was
introduced to emphasize the late-onset types of movement
disorders occurring during antipsychotic use. Yet the definition
of tardive disorders in the current study emphasizes their
persistence, which is clinically more important than their late-
onset [12,13]. Given that combinations of acute and chronic
movement disorders occur in patients undergoing long-term
treatment with antipsychotics, prediction models should include
both syndromes, i.e., the four major types of movement disorders
(TD, parkinsonism, akathisia and tardive dystonia). It is notewor-
thy that movement disorders may fulfill the criteria for classifying a
trait as a spectrum condition of a disorder, in this case
schizophrenia: heritability, familial link, co-segregation, and
biological and clinical plausibility [14]. Spectrum conditions refer
to mild psychopathology of little clinical significance among
relatives without the full disorder. The advantage for research of
spectrum conditions in contrast to a full disorder is that they may
have fewer risk factors and therefore a less complex chain of
mechanisms (pathways) leading to their onset, which could make
research easier to perform. (Pharmaco) genetic studies may help
elucidate these common pathways in the development of both
spectrum conditions and the full disorder. It is possible to
hypothesize that specific subtypes of movement disorders are
more suitable for genetic analysis than a general movement
disorder syndrome, as subtypes may better reflect the underlying
biological heterogeneity in complex syndromes.
The phenotypes under study were TD, parkinsonism, akathisia,
and tardive dystonia, subtypes of TD (orofacial and limb truncal
dyskinesia), subtypes of parkinsonism (rest tremor, rigidity, and
bradykinesia), as well as a principal-factor of the movement
disorders and their subtypes.
The 7 candidate genes were GRIN2B, GRIN2A, HSPG2, DRD3,
DRD4, HTR2C, and NQO1 (Text S1). The choice of these genes
was hypothesis-driven, under the common disease/common
variant (CDCV) hypothesis, which proposes that common diseases
may be caused by common genetic variants [15–18].
The aim of the current study was to determine the association
between movement disorders and variations in these 7 candidate
genes.
The prospective design of the current study extends hitherto
cross-sectional work in the pharmacogenetic field of antipsychotic-
induced movement disorders. Indeed, prospective assessment of
fluctuating (repeated) movement disorders measures the pheno-
type more specifically and that increases the validity of the
associations between movement disorders and risk factors.
Methods
Ethics Statement
The protocol was approved by the standing Institutional Review
Board, ‘Medisch-ethische Toetsingscommissie Instellingen Gees-
telijke Gezondheidszorg’ (Review Board for Human Research in
Psychiatry), the Netherlands [protocol number 377].
Written informed consent was obtained from each patient,
hence, consent obtained from the next of kin was not necessary
and not recommended by the Review Board for Human Research
in Psychiatry.
Subjects
A 4-year prospective naturalistic study (July 2003– May 2007)
was conducted with 209 patients with chronic mental illness in
order to determine the genetic risk factors of the four major types
of movement disorders (TD, parkinsonism, akathisia, and tardive
dystonia), subtypes of TD and parkinsonism, as well as a principal-
factor of the movement disorders and their subtypes. To this end,
a cohort was drawn from a general psychiatric hospital (GGZ
Centraal, Amersfoort, the Netherlands). Full details of the study
design and movement disorders have been published previously
[19] (Bakker and colleagues, submitted). The cohort was
representative of the population of patients with the most severe
chronic mental illness requiring long-stay care, given that the
hospital serves an epidemiological catchment area, is the only
institute providing this type of care in this area, and patients were
selected from a comprehensive list of all inpatients.
Of the patients assessed at baseline (N = 207) 93.7% (n = 194)
had at least one follow-up and 59.4% (n = 123) had two follow-up
assessments. Loss to follow-up was due to patients who were
difficult to trace after leaving hospital, died or refused assessment
after inclusion.
Assessment
Patients were examined by a trained psychiatrist (PRB), using a
standard protocol, described by van Harten and colleagues [20].
In addition, subtypes of movement disorders were assessed using (i)
the Abnormal Involuntary Movement Scale (AIMS) [21,22] with
items 1–4 for orofacial and items 5–7 for limb truncal dyskinesia,
(ii) the Unified Parkinson Disease Rating Scale (UPDRS) [23] with
item c3–c4 for ‘rest tremor’ (rest tremor, and action/postural
tremor of hands); item c5 for rigidity; and items c1, c2, c6–c12,
and c14 for bradykinesia. This approach has been described
previously by 3 members of our research team (AAH, JvO and
PNvH) [24–26].
As movement disorders likely share genetic liability, a genetic
association between the combined movement disorders and
candidate genes is also required. To determine the association
between the combined movement disorders and variation in 7
candidate genes, a principal-factor of the four major types of
movement disorders and subtypes of TD and parkinsonism was
calculated with the FACTOR procedure in the STATA statistical
program [27].
Based on the literature published between 1976 and July 2012,
we selected 7 candidate genes (Tables 1 and S1, and Text S1) that
are involved in the dopaminergic and serotonergic systems, and
protection of neurotoxicity, and we included the gene coding for
heparan sulfate proteoglycan 2, all which have been implicated in
the development of movement disorders.
In addition, variables possibly affecting risk were extracted from
patients’ case notes (Text S1).
Gene and Tag SNP Selection, DNA Extraction,
Genotyping
Two 10 ml EDTA tubes of peripheral blood were drawn from
participants, and genomic DNA was extracted from leucocytes by
Autopure LS method (Qiangen) according to the manufacturer’s
protocols.
Movement Disorders in Long-Stay Patients and Genes
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The tag SNPs were selected using a web-based tool freely
available on the internet (SNPinfo Web Server; http://www.niehs.
nih.gov/snpinfo) [48] (Text S1).
Statistical Analyses
Hardy weinberg equilibrium. Only SNPs were included in
the analyses that were not significantly outside Hardy-Weinberg
Equilibrium (HWE) (p.0.05) in (i) the complete control sample
(for a dichotomous trait) or (ii) the complete study sample (for a
continuous trait). For the six SNPs in the X-chromosomal HTR2C
gene, departure from HWE was not calculated.
Departure from the HWE was calculated with the GENASS
and GENHW procedures in the STATA statistical program [27]
for (i) the dichotomously defined persistent forms of movement
disorders separately in both patients (with one movement disorder)
and controls (without that movement disorder). Case definition of
a persistent movement disorder was based on 2 consecutive
assessments over a period of minimally 3 months, and required
that individuals met case definition criteria at two consecutive
assessments (hereafter: persistent movement disorder), meeting the
requirements of Schooler and Kane’s criteria for persistent
movement disorder [49], and (ii) the combined group of patients
and controls, as continuous measures cannot be separated in both
patients and controls.
Association tests for single tag SNPs. Only continuous
movement disorder outcomes were used, given that continuous
measures better handle the variability of movement disorders and
generate more statistical power than cut off points [50,51].
Genotype and allele frequency comparisons were performed with
multiple regression methods for continuous movement disorders,
using the Armitage trend test, with the major allele (from our
dataset of 168 selected white patients) as reference. The Armitage
trend test assumes an additive effect by both alleles on the trait of
interest, i.e. the mean effect on the trait by the heterozygous
genotype (Major-Minor) is halfway the effects of the two
homozygotes. (Major-Major and Minor-Minor).
Regression analyses. The regression analyses were con-
ducted with movement disorder measures at a single assessment
(hereafter: fluctuating movement disorder). The reason for this was
that movement disorders constantly fluctuate over time, so that
inclusion in the regression of their repeated single-occasion
measures allowed for calculation of associations between one
movement disorder with the other over time. As the study design
comprised repeated measures nested in the same patient,
clustering of observations in individuals needed to be corrected
for. Therefore, multilevel random regression was used with the
measurement occasion (baseline and two follow-ups) at level 1, and
subjects at level 2, with the XTREG MLE routine of the STATA
statistical program [27]. Associations with explanatory variables
were expressed as beta coefficients representing the change of
continuous movement disorder outcome with 1 unit change of the
exposure variable.
Using the dataset of 168 selected white patients, associations
with predictors were adjusted for a priori, movement-disorder
specific covariates as follows (Bakker and colleagues, submitted)
age was adjusted for in the model of TD and its subtypes; age and
total antipsychotic use was adjusted for in the model of
parkinsonism and its subtypes, and no covariates were introduced
in the models of akathisia, tardive dystonia and the principal-
factor.
Power calculations were performed using the Quanto program
version 1.2.4 (http://hydra.usc.edu/gxe).
Correction for multiple testing. In order to correct for
multiple testing of single SNP tests, the Simes modification of the
Bonferroni multiple-testing procedure was performed to control
the False Discovery Rate (FDR) [52]. Bonferroni correction is too
conservative if tests are not independent of each other; in this case
FDR represents a less conservative alternative. We used the
MULTPROC procedure in the STATA statistical program [27]
Figure 1. Smile plot summarizing set of multiple analyses after Simes correction for multiple testing of tag SNPs without HWE
deviation. Corresponding p-values (on a reverse log scale against the corresponding parameter estimates). TD= tardive dyskinesia, OF =orofacial
dyskinesia, LT = limb truncal dyskinesia, PK = parkinsonism, RT= rest tremor, RG= rigidity, BK = bradykinesia, AK = akathisia,TDt = tardive dystonia.
doi:10.1371/journal.pone.0050970.g001
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for FDR calculation, and then the SMILEPLOT procedure
calling MULTPROC to build a smile plot. A smile plot
summarizes a set of multiple analyses, similarly as a Cochrane
forest plot summarizes a meta-analysis, and separates by reference
line rejected and non-rejected p-values (on a reverse log scale
against the corresponding parameter estimates).
Defined daily dose. Antipsychotic doses were converted to
defined daily dose (DDD), for which we refer to our previous
publication [19]. Anticholinergic medication was modeled as a
dichotomous variable (yes/no).
Results
Sample Characteristics
Over the period of observation (mean = 1.1 years, SD = 0.64), of
the 209 patients included at baseline, 207 participated in the study.
One patient developed a brain tumor, another patient died after
inclusion. All patients had a history of cumulative antipsychotic
intake of minimally 1 year. Attrition rate was low at 9.8% over a 4-
year period.
Of the 207 patients, with chronic psychiatric illness requiring
long-term admission, 199 participated in the genetic study. To
prevent ethnic stratification resulting in spurious associations
owing to differences in allele frequencies and risk of movement
disorders, only white patients, representing the most prevalent
group (168 = 84.4%), were included in the analysis. At baseline,
mean age expressed in years was 48.8 (SD 12.4); men 48.6 (SD
12.5) and women 49.1 (SD 12.2). Age at first admission, expressed
in years, was 25.1 (SD 8.8); men 23.7 (SD 7.8) and women 27.1
(SD 9.7). The total duration of admission, expressed in years, was
23.4 (SD 12.9), men 24.4 (SD 12.5) and women 22.0 (SD 13.4).
Diagnoses according to DSM-IV Axis I as defined above were:
schizophrenia 112 (66.7%), psychosis 9 (5.4%), affective disorder
27 (16.1%), other Axis I diagnosis 11 (6.6%) and no Axis I
diagnosis 9 (5.4%).
Association Analyses with Tag SNPs
The following SNPs were excluded from analysis, due to
deviation from HWE: all movement disorders – rs6698486,
rs11721264, rs167770, rs3758653 and rs1800566, as well as
controls, TD – rs10845838, rs7206256 and rs7633291; orofacial
dyskinesia – rs10845838 and rs2445142; limb truncal dyskinesia –
rs7633291; parkinsonism, rest tremor and bradykinesia –
rs2445142. In addition, rs12300851 was removed as it contained
only A alleles.
The (multilevel) regression yielded significant coefficients, after
adjustment for age, between TD and rs1345423 (B =20.13,
p = 0.0421), rs7192557 (B = 0.22, p = 0.0159), rs1650420
(B = 0.16, p = 0.0193), as well as rs11644461 (B =20.13,
p = 0.0385); between orofacial dyskinesia and rs7192557
(B = 0.22, p = 0.0291), rs1650420 (B = 0.16, p = 0.0336), as well
as rs4911871 (B =20.18, p = 0.0131); between limb truncal
dyskinesia and rs1345423 (B =20.18, p = 0.0190), rs7192557
(B = 0.22, p = 0.0430), rs1650420 (B = 0.16, p = 0.0471), as well as
rs11866328 (B = 0.16, p = 0.0330). After adjustment for age and
total DDD equivalents, associations were apparent between
bradykinesia and rs2192970 (B =20.16, p = 0.0349). Without
adjustment, associations were apparent between akathisia and
rs324035 (B =20.20, p = 0.0392), as well as the principal-factor
and rs10772715 (B =20.20, p = 0.0362). After Simes correction
for multiple testing of the above mentioned analyses, the number
of rejected p-values was zero, with a corrected overall critical p-
value of 0.00013 (Figure 1).
Power calculations showed that our sample was insufficiently
powered (0.05) to identify the betas from our regressions, which
were between 20.34 and 0.25.
Discussion
In a population with chronic mental illness, various tag SNPs in
7 candidate genes (GRIN2B, GRIN2A, HSPG2, DRD3, DRD4,
Figure 2. Smile plot summarizing set of multiple analyses after Simes correction for multiple testing of all tag SNPs. Corresponding p-
values (on a reverse log scale against the corresponding parameter estimates). TD= tardive dyskinesia, OF= orofacial dyskinesia, LT = limb truncal
dyskinesia, PK= parkinsonism, RT= rest tremor, RG= rigidity, BK = bradykinesia, AK = akathisia,TDt = tardive dystonia.
doi:10.1371/journal.pone.0050970.g002
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HTR2C, and NQO1) reached nominally significant (p#0.05)
associations with drug-induced movement disorders. However,
after controlling for multiple testing, our findings suggest that these
tag SNPs are not associated with a susceptibility to movement
disorders.
Another reason for the inconclusive findings could be explained
by the fact that in a naturalistic setting it is possible to evaluate the
overall impact of pharmacogenetic signals in the presence of a host
of real-life variables that can override pharmacogenetic variation.
The fact we did not observe a significant association may also
attest to the possibility that each gene makes a small contribution
that is often diluted or overridden by environmental and clinical
variations.
Limitations
This study had limitations, for which we refer to our previous
publications [19,53] (Bakker and colleagues, submitted) as well
point to additional limitations. First, some authors may argue that
the SNPs with HWE deviation should not be excluded from the
analyses, as SNPs in HWE could in reality be also out of HWE
owing to lack of power. Therefore, we performed a post-hoc analysis
with all SNPs, i.e., also those deviating from HWE, which resulted
in one extra nominal significant result, which also did not survive
Simes correction for multiple testing (Figure 2). Second, the choice
to genotype tag SNPs in the candidate genes, and not only the
specific SNPs that were previously associated with movement
disorders, increased the multiple testing burden. However, tag
SNPs are a relatively small set of common polymorphisms [54] in
the candidate genes providing maximum information; therefore,
they may reveal new (unknown) SNPs in linkage disequilibrium
related to movement disorders. Third, the inclusion of patients
with various psychiatric illnesses, not only schizophrenia, may
result in spurious associations.
Strengths
We refer to our previous publications [19,53] (Bakker and
colleagues, submitted). The importance of repeated measures
should be noted, as case definition of repeated measures, rather
than a single cross-sectional measure, for continuous movement
disorders better reflects the continuously fluctuating nature in time
of both acute and chronic movement disorders, and therefore may
represent a more suitable standard in future research. To the best
of our knowledge only few papers in the literature address this
issue.
As the sample size of the current study is small and previous
studies show inconsistent results, definite conclusions cannot be
made. Yet the question is how to interpret these results. In our
opinion, the findings of weak genetic signals need to be replicated
in larger study samples, preferably in longitudinal studies which
take the fluctuating course of movement disorders and gene-
environment interactions into account [55,56].
Even though the current study is inconclusive, the importance
of negative findings should not be underestimated as they can
inform future meta-analysis, which otherwise might be biased by
excess significance bias occasioned by selection of positive studies
for publication. The pioneering meta-analyses of Lerer and
colleagues [31,57] showed that with meta-analysis, synthesis of
association studies for TD can be accomplished; it was shown that
small effects may point to the involvement of other genes in the
development of TD. In recent years, genome-wide association
studies (GWASs) revealed several SNPs related to movement
disorders including tardive dyskinesia [29,30,58,59] and parkin-
sonism [60,61]. We further refer to our previous publication [53].
All in all, it seems legitimate to conclude that future research
projects into antipsychotic-induced movement disorders may take
advantage of a new perspective on common pathways of
movement disorders. Directed acyclic graphs (DAGs, also known as
‘‘causal diagrams’’ or ‘‘causal pathways’’) allow pathways to be
visualized by analytical graphs and conceptualize the relationships
between all of the important variables (e.g., schizophrenia,
movement disorder, antipsychotics, genes, etc.) as a precise
theoretical model. DAGs depict explicitly, in an easy and flexible
way, confounding effects (‘‘backdoor paths’’) and collider effects
(two causal pathways). The latter is important as adjusting for
colliders creates confounding [62](p161) [63](p183). Rothman’s
sufficient-component cause model (or sufficient-cause model)
permits the postulation of different sufficient causes comprising a
collection of collaborating risk factors (also known as ‘‘causal
components’’) ‘‘sufficient to produce the disease in the individual’’
[63](p8). This model can also identify proximal (biological markers of
risk), intermediate, and distal sufficient causes, hence describing a
chain of causality [62](p379).
The sufficient-component cause model shows that risk factors in
complex diseases plausibly interact non-additively, since these risk
factors may be neither necessary nor sufficient to produce disease,
and frequently co-participate in similar pathways [63](p81) [64,65].
Although in psychiatry there is great interest in these interactions
(gene-environment, environment-environment and gene-gene),
concerns are being raised about the correct underlying interaction
model (additive versus multiplicative), as are doubts about the
recent interpretation of pathogenesis increasingly identified in a
growing number of interaction studies [66].
New research designs to help understand gene-environment
causality are in progress. For example, contrary to between-subject
cross-sectional designs, longitudinal within-subject (longitudinal
and multilevel) designs with repeated assessments [67] are being
implemented. They have the advantage of being free of between-
subject confounding [68], may reveal the dynamics of behavior
(movements), and therefore elucidate gene-environment causality.
Of importance are the so called momentary assessment tools [69],
examples being the Experience Sampling Method (ESM) by
Csikszentmihalyi and Larson [70] and ‘PsyMate’ by Myin-
Germeys [71].
In addition, future research may be served by data-intensive
science that concentrates on sharing and integrating selected data
sets [72]. As rightly stated by Chalise and colleagues [73], new sets
of integrative genomic approach, i.e., the collection of different
types of genomic data, do more justice to the complexity of drug-
related phenotypes, than most of the existing ‘‘naı¨ve one-at-a-time
analysis approach’’ which overlooks this complexity. Important
initiatives are (i) the EUropean network of national schizophrenia
networks studying Gene-Environment Interactions (EU-GEI,
www.eu-gei.eu) and (ii) the Network of Investigator Networks
sponsored by the global Human Genome Epidemiology Network
(HuGENet, www.cdc.gov/genomics/hugenet) [74]. An important
issue concerns the identification of significant SNPs in the genome,
e.g. from genome-wide association studies (GWASs) [75].
In conclusion, the findings suggest that selected tag SNPs are
not associated with a susceptibility to movement disorders.
However, replication is needed in larger study samples, preferably
in longitudinal studies which take the fluctuating course of
movement disorders and gene-environment interactions into
account. The use of intermediate phenotypes, for example,
laboratory based phenotypes [76], or more accurate measures of
movement disorders, for example instrument measurement of
lingual force variability as proposed by Koning and colleagues
[77], which may represent a powerful alternative since instrument
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measurement detects subclinical movement disorders and is highly
reliable. Moreover, (pharmaco) genetic studies may help elucidate
common pathways in the development of movement disorders.
Future research on movement disorders may be served by the
inclusion of all four movement disorders, as performed in the
current study, since they may represent pleiotropic effects from
(partly) shared genetic factors [78].
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(DOC)
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